Abstract
Pharmacology Mitogen-activated protein kinase (MAPK) phosphatases (MKPs) have roles in many diseases but have been considered “undruggable” because of their high degree of conservation. Gannam et al. identified and characterized a small molecule that inhibited MKP5 but did not affect the activity of related phosphatases. In muscle cells, the inhibitor blocked MKP5 from inactivating the MAPKs and inhibited a signaling pathway that promotes fibrosis in dystrophic muscle disease. These results demonstrate that it is possible to target MKPs with a high degree of specificity. Sci. Signal. 13 , eaba3043 (2020).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
